Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.

Davis JM, Ivanova A, Chung Y, Shaw JR, Rao KV, Ptachcinski JR, Sharf AA, Serody JS, Armistead PM, Wood WA, Coghill JM, Jamieson KJ, Vincent BG, Riches ML, Shea TC, Alexander MD.

Biol Blood Marrow Transplant. 2019 Feb;25(2):391-397. doi: 10.1016/j.bbmt.2018.09.017. Epub 2018 Sep 19.

PMID:
30244102
2.

The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.

Willcox A, Wong E, Nath C, Janson B, Harrison SJ, Hoyt R, Bajel A, Shaw P, Ritchie D, Grigg A.

Ann Hematol. 2018 Dec;97(12):2509-2518. doi: 10.1007/s00277-018-3447-x. Epub 2018 Jul 26.

PMID:
30051172
3.

Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy.

Browning B, Thormann K, Donaldson A, Halverson T, Shinkle M, Kletzel M.

Biol Blood Marrow Transplant. 2011 Sep;17(9):1383-8. doi: 10.1016/j.bbmt.2011.01.013. Epub 2011 Feb 1.

4.

Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation.

Cho SH, Lee JH, Lim HS, Lee KH, Kim DY, Choe S, Bae KS, Lee JH.

Korean J Physiol Pharmacol. 2016 May;20(3):245-51. doi: 10.4196/kjpp.2016.20.3.245. Epub 2016 Apr 26.

5.

Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.

Zao JH, Schechter T, Liu WJ, Gerges S, Gassas A, Egeler RM, Grunebaum E, Dupuis LL.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1471-8. doi: 10.1016/j.bbmt.2015.05.006. Epub 2015 May 11.

6.

Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.

Gaziev J, Nguyen L, Puozzo C, Mozzi AF, Casella M, Perrone Donnorso M, Gravina P, Sodani P, Marziali M, Isgrò A, Simone MD, Andreani M, Formosa A, Testi M, Federici G, Bernardini S, Lucarelli G.

Blood. 2010 Jun 3;115(22):4597-604. doi: 10.1182/blood-2010-01-265405. Epub 2010 Mar 17.

7.

Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.

Rhee SJ, Lee JW, Yu KS, Hong KT, Choi JY, Hong CR, Park KD, Shin HY, Song SH, Kang HJ, Lee H.

Am J Hematol. 2017 Jul;92(7):607-613. doi: 10.1002/ajh.24734. Epub 2017 May 30.

8.

Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.

Lindley C, Shea T, McCune J, Shord S, Decker J, Harvey D, Petros WP, Garbriel D, Serody J, Kirby S, Wiley J.

Anticancer Drugs. 2004 Jun;15(5):453-9.

PMID:
15166618
9.

Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation.

Ward J, Kletzel M, Duerst R, Fuleihan R, Chaudhury S, Schneiderman J, Tse WT.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1612-21. doi: 10.1016/j.bbmt.2015.05.017. Epub 2015 May 27.

10.

Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?

Clemmons AB, Evans S, DeRemer DL, Awan FT.

J Oncol Pharm Pract. 2015 Dec;21(6):425-32. doi: 10.1177/1078155214541571. Epub 2014 Jul 1.

PMID:
24986792
11.

The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.

Tesfaye H, Branova R, Klapkova E, Prusa R, Janeckova D, Riha P, Sedlacek P, Keslova P, Malis J.

Ann Transplant. 2014 May 9;19:214-24. doi: 10.12659/AOT.889933.

12.

Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation.

Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P.

Biol Blood Marrow Transplant. 2017 Jun;23(6):952-957. doi: 10.1016/j.bbmt.2017.02.020. Epub 2017 Mar 10.

14.

Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

Brooks KM, Jarosinski P, Hughes T, Kang E, Shah NN, Gall JBL, Hickstein DD, De Ravin SS, George JM, Kumar P.

J Clin Pharmacol. 2017 Dec 14. doi: 10.1002/jcph.1049. [Epub ahead of print]

PMID:
29238995
15.

Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.

Nguyen L, Leger F, Lennon S, Puozzo C.

Cancer Chemother Pharmacol. 2006 Jan;57(2):191-8. Epub 2005 Aug 25.

PMID:
16133536
16.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

17.

Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.

Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ.

Lancet Haematol. 2016 Nov;3(11):e526-e536. doi: 10.1016/S2352-3026(16)30114-4. Epub 2016 Oct 13.

18.

Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.

Wall DA, Chan KW, Nieder ML, Hayashi RJ, Yeager AM, Kadota R, Przepiorka D, Mezzi K, Kletzel M; Pediatric Blood, Marrow Transplant Consortium.

Pediatr Blood Cancer. 2010 Feb;54(2):291-8. doi: 10.1002/pbc.22227.

PMID:
19743300
19.

Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.

Tran H, Petropoulos D, Worth L, Mullen CA, Madden T, Andersson B, Choroszy M, Nguyen J, Webb SK, Chan KW.

Biol Blood Marrow Transplant. 2004 Nov;10(11):805-12.

20.

Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.

Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, Dupuis LL.

Biol Blood Marrow Transplant. 2007 Mar;13(3):307-14.

Supplemental Content

Support Center